

DP-Filter®

For Removal of DOACs from Plasma Specimens

REF 5D-82412-RUO**FOR IN VITRO USE ONLY. FOR RESEARCH USE ONLY.
NOT FOR USE IN DIAGNOSTIC PROCEDURES.**

Store at Room Temperature

DESCRIPTION

One box contains 25 ready-to-use DP-Filter®.

INTENDED USE

The DP-Filter® is a device for the filtration of citrated plasmas to remove Direct Oral Anticoagulants (DOAC) including dabigatran, edoxaban, apixaban and rivaroxaban at concentrations from 0,000 to 1,000 ng/mL.

APPLICATION

Aiding hemostasis research laboratories to develop more sophisticated methods for diagnosing hemostatic disorders. The study of blood parameters of patients under DOAC therapy is challenging and may lead to false results. The DP-Filter® is effective in filtering DOAC from citrated plasma providing anticoagulant-free plasma that can be used for testing.

PROCEDURE

Specimens should be prepared and stored in accordance with applicable local guidelines (for the United States, see the CLSI H21-A5 guidelines for further information on collection, handling and storage). DP-Filter® can be used with frozen plasma after thawing.

1. Add 500 µL of plasma on the upper side of the DP-Filter.
2. Vortex the device.
3. Incubate the device 5 minutes at room temperature.
4. Centrifuge the device 2 minutes at 200g. Plasma must be fully passed through the filter.
5. Remove the upper filter from the device.
6. The collected plasma (free from DOAC) can be used for testing or can be frozen for later analysis.

STORAGE AND STABILITY

Store in a dry place at ambient temperature (15-30°C) in its original packaging.

WARNINGS AND PRECAUTIONS

For In Vitro Use Only. For Research Use Only. Not for Use in Diagnostic Procedures.

It is not recommended to use lyophilized, highly lipemic or hemolyzed plasma with the DP-Filter®.

REFERENCES

1. Clinical and Laboratory Standards Institute (CLSI). Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline-Fifth Edition, CLSI document H21-A5 (ISBN 1-56238-657-3)
2. Favresse, J. *et al.* Neutralization of biotin interference: preliminary evaluation of the VeraTest Biotin™, VeraPrep Biotin™ and BioT-Filter® Clinical Chemistry and Laboratory Medicine (CCLM), Volume 58, Issue 8, Pages e130–e133, eISSN 1437-4331, ISSN 1434-6621
3. Lessire S, Dincq A-S, Siriez R, *et al.* Assessment of low plasma concentrations of apixaban in the periprocedural setting. *Int J Lab Hematol.* 2020;00:1–9. <https://doi.org/10.1111/ijlh.13202>
4. Siriez R, Dogné J-M, Gosselin R, Laloy J, Mullier F, Douxfils J. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory. *Int J Lab Hematol.* 2020;00:1–14. <https://doi.org/10.1111/ijlh.13342>